# Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

> **NCT01786603** · PHASE2 · COMPLETED · sponsor: **Richard Barohn, MD** · enrollment: 80 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** Rasagiline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01786603
- **Lead sponsor:** Richard Barohn, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-21
- **Primary completion:** 2016-07-27
- **Final completion:** 2016-07-27
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01786603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01786603, "Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01786603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*